Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Jan 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Large cash cushion ⢠No revenue ⢠Reliance on financing RAPP is cashârich with minimal debt but currently preârevenue, burning substantial cash through operating losses and heavy investing that relies on external financing, risking sustainability if funding tightens.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Repeated support ⢠Resistance zone Support Level: $27.00 Resistance Level: $30.00â$31.00 RAPP has shown volatile but weakening price action over the last month, falling from about $30.93 to $27.10 with repeated tests of $27.00 support and resistance near $30â$31 suggesting mounting selling pressure unless $27.00 holds.
Sentiment & News
Key News Insights: ⢠Phase 3 clearance ⢠Institutional stake ⢠Insider sales Rapport Therapeutics cleared a major regulatory and clinical inflection point as the FDA greenlit accelerated Phase 3 development for RAP-219 while expanding its epilepsy and other programs amid growing institutional buying and routine insider sales.
AI Summary
RAPP has transitioned from a speculative discovery play to a registrational-stage company where value now hinges on flawless Phase 3 execution for RAPâ219 and disciplined capital management given a funded runway into H2â2029. Monitor Phase 3 design/enrollment milestones, interim efficacy/safety readouts, and any partnership or funding moves as the primary drivers of upside or dilution risk.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |